Skip to main content

ImmunityBio, Inc 10-Q for FY2026 Q3

ImmunityBio, Inc. (IBRX)

10-Q 2026-11-09 For: 2026-09-30
View Original
Added on November 09, 2026

About this 10-Q

ImmunityBio, Inc filed this 10-Q on November 9, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

ImmunityBio reported ANKTIVA’s October 14, 2026 FDA approval for BCG-unresponsive NMIBC with high-grade papillary-only tumors and Q3 2026 net product revenue of $48.7 million, up 53% year-over-year. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$48.84M
up 52.3% from $32.06M a year earlier
Net loss
$184.55M
compared with a net loss of $67.25M a year earlier
Diluted EPS
-$0.18
compared with -$0.07 a year earlier